1,6-dimethyl-1,2,3,4-tetrahydro-pyridine | 15032-01-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1,6-dimethyl-1,2,3,4-tetrahydro-pyridine
• 英文别名: 1,2-Dimethyl-1,4,5,6-tetrahydropyridin；1,6-Dimethyl-1,2,3,4-tetrahydro-pyridin；1,2-Dimethyl-Δ²-piperidein；1,2-Dimethyl-Δ²-piperidin；Pyridine, 1,4,5,6-tetrahydro-1,2-dimethyl-；1,6-dimethyl-3,4-dihydro-2H-pyridine
• CAS: 15032-01-6
• 化学式: C₇H₁₃N
• 分子量: 111.187
• InChiKey: UESXQASBXUNZTI-UHFFFAOYSA-N

物化性质

• 沸点：
  71-72 °C(Press: 62 Torr)
• 密度：
  0.863±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,6-dimethyl-1,2,3,4-tetrahydro-pyridine 在 甲酸 、 potassium formate 作用下， 生成 1,2-二甲基哌啶
  参考文献：
  名称：

  Lukes; Cervinka, Collection of Czechoslovak Chemical Communications, 1959, vol. 24, p. 309

  摘要：

  DOI：
• 作为产物：
  描述：

  1,2-二甲基哌啶 在 mercury(II) diacetate 、 溶剂黄146 作用下， 生成 1,6-dimethyl-1,2,3,4-tetrahydro-pyridine
  参考文献：
  名称：

  Unsaturated Amines. X. The Mercuric Acetate Route to Substituted Piperidines, Δ²-Tetrahydropyridines and Δ²-Tetrahydroanabasines

  摘要：

  DOI：

  10.1021/ja01576a056

文献信息

• [EN] ENGINEERED ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS<br/>[FR] ANTICORPS CONÇUS COMME AGENTS DE DÉGRADATION MOLÉCULAIRE PAR L'INTERMÉDIAIRE DE RÉCEPTEURS CELLULAIRES
  申请人：UNIV YALE

  公开号：WO2021072246A1

  公开（公告）日：2021-04-15

  The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In certain embodiments, the circulating protein mediates a disease and/or disorder in a subject, and treatment or management of the disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein in the subject. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the circulation concentration of the circulating protein, thus treating, ameliorating, or preventing the disease and/or disorder.

  本公开提供了一种双功能化合物，可用于促进或增强特定循环蛋白的降解。在某些实施例中，循环蛋白在受试者中介导疾病和/或紊乱，治疗或管理该疾病和/或紊乱需要降解、去除或减少受试者中循环蛋白的浓度。因此，在某些实施例中，将本公开的化合物给予受试者可去除或减少循环蛋白的循环浓度，从而治疗、改善或预防疾病和/或紊乱。
• FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：Seko Takuya

  公开号：US20080261947A1

  公开（公告）日：2008-10-23

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  式（I）所表示的融合吡嗪衍生物或其药学上可接受的盐（其中每个符号的含义如规范中所定义）。由于抑制了聚(ADP-核糖)聚合酶，式（I）所表示的化合物可用作预防和/或治疗各种缺血性疾病（在大脑、脊髓、心脏、消化道、骨骼肌、视网膜等部位），炎症性疾病（炎症性肠病、多发性硬化症、关节炎等），神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌萎缩症、腰椎管狭窄等），糖尿病、休克、头部创伤、肾功能衰竭、高痛感等。此外，这些化合物还可用作抗逆转录病毒剂（HIV等）、治疗癌症的增敏剂和免疫抑制剂。
• FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS
  申请人：AMGEN INC.

  公开号：US20140350244A1

  公开（公告）日：2014-11-27

  Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of CDK4-mediated disorders, such as cancer. The subject compounds are fused pyridine, pyrimide and triazine derivatives.

  本发明提供了在治疗CDK4介导的疾病，如癌症中有用的化合物、制药组合物和方法。所述化合物为融合的吡啶、嘧啶和三嗪衍生物。
• Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP2281818A1

  公开（公告）日：2011-02-09

  Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.

  式 (I) 所代表的融合哒嗪衍生物或其药学上可接受的盐（其中各符号的含义如说明书中所定义）。 由于能抑制多（ADP-核糖）聚合酶，式（I）代表的化合物可作为各种缺血性疾病（脑、脊髓、心脏、消化道、骨骼肌、视网膜等）、炎症性疾病（炎症性肠病）的预防和/或治疗药物。炎症性疾病（炎症性肠病、多发性脑硬化症、关节炎等）、神经退行性疾病（锥体外系障碍、阿尔茨海默病、肌肉萎缩症、腰椎管狭窄症等）、糖尿病、休克、头部创伤、肾功能衰竭、痛觉减退等。此外，这些化合物还可用作抗逆转录病毒（HIV 等）的药物、治疗癌症的增敏剂和免疫抑制剂。
• Moehrle, H.; Claas, M., Pharmazie, 1988, vol. 43, # 11, p. 749 - 753
  作者：Moehrle, H.、Claas, M.

  DOI：——

  日期：——